Shattuck Labs Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
4.9%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$0.48next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Expected Q3 2026 Financial Results Release | 5 Nov 2026 |
| Expected Phase 2b RECEPTIVE-CD1 12-Week Induction Data Release | 30 Jun 2028 |
Monitoring Framework
Key Performance Indicators
SL-325 Phase 1 Healthy Volunteer Trial Enrollment Quarterly72.0
SL-325 Phase 1 Anti-Drug Antibody (ADA) Rate Quarterly370.0%Target: Low single-digit ADA rate consistent with Phase 1 (3.7%)
Cash and Short-Term Investments (USD Millions) Quarterly90.4
Watch Items
- Initiation of RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's diseaseTrigger: Q3 2026Action: Confirm first patient dosed and trial design alignment with regulators.
- IND-enabling GLP toxicology study of SL-846 in non-human primatesTrigger: H2 2026Action: Review safety, tolerability, and immunogenicity data readouts.
- IND filing for SL-846 (DR3 x IL-23R bispecific antibody)Trigger: H1 2027Action: Submit Investigational New Drug application to the FDA.
Research as of 20 Jun 2026